All In Biotech

Drug Trial Radar · NCT05476939

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 433 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

433

Planned (sponsor's estimate)

Start

Sep 29, 2022

Primary completion

Sep 2028

Study completion Sep 2031

Sponsor

Lead sponsor
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Innovative Therapies For Children with Cancer Consortium; Ministry of Health, France; Jazz Pharmaceuticals
First posted
Jul 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The BIOMEDE 2.0 study is the second stage of the BIOMEDE multi-arm, multistage rolling programme (adaptive platform protocol). It is a multicenter, randomized, open-label, controlled phase-3 trial evaluating efficacy of ONC201 in comparison with everolimus (primary objective based on internal comparison) and subsequently to historical controls. Two treatment groups will be compared. A switch between treatment groups is allowed after confirmation of the disease progression (real-time central review blinded to the treatment arm allocation). Study treatment will be continued until centrally confirmed disease progression (either radiologically or histologically), unacceptable toxicity or consent withdrawal. The final conclusion of the trial will be successful for ONC201, if ONC201 is found significantly superior to everolimus in terms of centrally-reviewed PFS (Progression-free survival) from randomization (internal comparison) either overall, considering ND-DMG and DIPG-patients together, or in the subgroup of ND-DMG patients alone. In other cases, Everolimus will remain the standard arm unless it appears associated with an excess of toxicity compared to ONC201 which could then be discussed as a new standard.

Conditions

  • Diffuse Intrinsic Pontine Glioma
  • Diffuse Midline Glioma, H3 K27M-Mutant
  • Diffuse Midline Glioma, H3K27-altered

Interventions

  • EverolimusDrug

    Tablets of 2.5 mg or 10 mg. The prescribed dose is 5 mg/m²/day, orally, once daily. Dose will be capped at 10 mg once daily.

  • ONC201Drug

    Capsules of 125mg. The prescribed dose is 375mg/m², orally, once daily at Day 1 and Day 2 of each week. Dose will be capped at 625 mg per dose.

  • RadiotherapyRadiation

    All patients will be treated with 30 conventional single daily fractions of 1.8 Gy to a total of 54 Gy over a planned period of 6 weeks. Dose may be increased up to 60 Gy for adult patients with supratentorial ND-DMG. The clinical target volume will include all the areas of abnormality on T2/FLAIR sequences with a 1-cm margin. Radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery. The study medication will be started at Day 1 (+3 days max) of radiotherapy. Reirradiation is permitted only at disease progression according to local practice. In case of metastatic disease or intramedullary tumors, patients can be included in the study. In this situation, radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery while targeted treatment will start at the end of the irradiation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survivalTime frame: Until 2 years after inclusion of the last patient

Locations

56 sites in 8 countries. Site status is shown where the registry gives one.

  • Cliniques Universitaires Saint-Luc (CUSL)

    Brussels, Belgium · Recruiting

  • University Hospital Leuven (UZ Leuven)

    Leuven, Belgium · Recruiting

  • Aarhus Universitetshospital Skejby

    Aarhus, Denmark · Recruiting

  • Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • H.C. Andersen Children's Hospital, Odense Universitetshospital

    Odense, Denmark · Recruiting

  • Helsinki University Hospital

    Helsinki, Finland · Recruiting

  • CHU d'Amiens-Picardie Site Sud

    Amiens, France · Recruiting

  • Institut de Cancérologie de l'Ouest (ICO) - Site Paul Papin

    Angers, France · Recruiting

  • CHU d'Angers - Bâtiment Robert Debré

    Angers, France · Recruiting

  • CHU Besançon - Hôpital Jean Minjoz

    Besançon, France · Recruiting

  • CHU de Bordeaux - Groupe hospitalier Saint André - Hôpital Saint André

    Bordeaux, France · Recruiting

  • CHU de Bordeaux - Groupe hospitalier Pellegrin - Hôpital des enfants

    Bordeaux, France · Recruiting

  • CHRU de Brest - Hôpital Morvan

    Brest, France · Recruiting

  • CHU de Caen - Hôpital Côte de Nacre

    Caen, France · Recruiting

  • CHU Estaing

    Clermont-Ferrand, France · Recruiting

  • Centre Jean Perrin

    Clermont-Ferrand, France · Recruiting

  • CHU François Mitterrand

    Dijon, France · Recruiting

  • CHU Grenoble Alpes - Hôpital Albert Michallon

    Grenoble, France · Not yet recruiting

  • CHU Grenoble Alpes - Hôpital Couple-Enfant

    Grenoble, France · Recruiting

  • Centre Oscar Lambret

    Lille, France · Recruiting

  • Hôpital Roger Salengro

    Lille, France · Not yet recruiting

  • Hôpital de la mère et de l'enfant

    Limoges, France · Recruiting

  • Centre Léon Bérard

    Lyon, France · Recruiting

  • Hôpital Pierre Wertheimer

    Lyon, France · Recruiting

  • Hôpital de La Timone

    Marseille, France · Recruiting

  • Hôpital Arnaud de Villeneuve

    Montpellier, France · Recruiting

  • CHRU Nancy - Hôpital central

    Nancy, France · Recruiting

  • CHRU Nancy Brabois - Hôpital d'enfants

    Nancy, France · Recruiting

  • CHU de Nice - Hôpital Pasteur 2

    Nice, France · Recruiting

  • CHU de Nice - Hôpital L'Archet 2

    Nice, France · Recruiting

  • Hôpital Saint Louis

    Paris, France · Recruiting

  • Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix

    Paris, France · Recruiting

  • Institut Curie

    Paris, France · Recruiting

  • CHU Poitiers

    Poitiers, France · Recruiting

  • CHU de Reims - American Memorial Hospital 2

    Reims, France · Recruiting

  • Centre Eugène Marquis

    Rennes, France · Recruiting

  • CHU Rennes - Hôpital Sud

    Rennes, France · Recruiting

  • CHU Rouen Normandie - Hôpital Charles-Nicolle

    Rouen, France · Recruiting

  • CHU de Saint-Denis de La Réunion

    Saint-Denis, France · Recruiting

  • CHU de Saint-Etienne - Hôpital Nord

    Saint-Etienne, France · Recruiting

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.